Wenwei Huang is a chemistry lead the Therapeutics for Rare and Neglected Diseases program in the Therapeutic Development Branch within NCATS’ Division of Preclinical Innovation, where he has worked in various therapeutic areas, including oncology, neurological disorders, inflammation and infectious diseases. Through a collaboration with New York University, Huang developed a series of RORg inhibitors that was licensed to Orca Pharmaceuticals.
Before joining NIH in 2006, Huang worked at ArQule, where his research focused on high-throughput chemistry.
Huang received his doctorate from the University of Toronto and conducted his postdoctoral research at Emory University.
Huang is interested in medicinal chemistry and high-throughput chemistry. His current research focuses on developing drugs that block malaria transmission.